{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:07Z","timestamp":1792103827171,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC0908903"],"award-info":[{"award-number":["2017YFC0908903"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.hbpd.2021.06.009","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T14:39:40Z","timestamp":1625668780000},"page":"416-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment"],"prefix":"10.1016","volume":"20","author":[{"given":"Xiu-Juan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Bao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Jiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Ming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hua","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2021.06.009_bib0001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0002","article-title":"Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0003","article-title":"Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0004","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2014.12.001","article-title":"Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease","volume":"26","author":"Pais","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0005","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s10620-014-3180-9","article-title":"Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors","volume":"59","author":"Wang","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0007","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0008","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cgh.2017.12.018","article-title":"Hepatic steatosis and its effects on fibrosis in patients with chronic hepatitis B virus infection","volume":"16","author":"Garcia-Saenz-de-Sicilia","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cld.2019.05.001","article-title":"The effects of hepatic steatosis on the natural history of HBV infection","volume":"23","author":"Suliman","year":"2019","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0012","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/hep.29252","article-title":"Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study","volume":"66","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0014","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","article-title":"Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients","volume":"26","author":"Machado","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0013","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.28917","article-title":"Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study","volume":"65","author":"Joo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.14309\/ajg.0000000000000588","article-title":"Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"115","author":"Chan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12878","article-title":"Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: a case-control study with propensity score analysis","volume":"25","author":"Zhong","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0016","first-page":"jiaa266","article-title":"Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blinded, placebo-controlled trial","author":"Rong","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0018","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1745-6215-15-438","article-title":"Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial","volume":"15","author":"Qu","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0021","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1751-2980.2008.00331.x","article-title":"Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases","volume":"9","author":"Zeng","year":"2008","journal-title":"J Dig Dis"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0023","unstructured":"U.S. Food and Drug Administration (FDA) Guidance for Industry. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Available from: https:\/\/www.federalregister.gov\/documents\/2018\/12\/04\/2018-26333\/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment-draft"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0024","unstructured":"National Medical Products Administration of China, Guiding principles for clinical trials of nonalcoholic steatohepatitis drugs (for trial implementation) (No. 92 of 2019). Available from: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20191220141201879.html"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0028","doi-asserted-by":"crossref","first-page":"e34198","DOI":"10.1371\/journal.pone.0034198","article-title":"Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B","volume":"7","author":"Jin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0027","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1478-3231.2007.01482.x","article-title":"Impact of non-alcoholic fatty liver disease on chronic hepatitis B","volume":"27","author":"Bondini","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0026","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0025","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.dld.2017.03.013","article-title":"A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B","volume":"49","author":"Xu","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0030","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7863\/ultra.16.04076","article-title":"Sonography predicts liver steatosis in patients with chronic hepatitis B","volume":"36","author":"Kelly","year":"2017","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0029","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/liv.14344","article-title":"Hepatitis B virus activity is not associated with degree of liver steatosis in patients with hepatitis B-related chronic liver disease","volume":"40","author":"Worland","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0031","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0032","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2478\/jtim-2019-0023","article-title":"Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient","volume":"7","author":"Alam","year":"2019","journal-title":"J Transl Int Med"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0034","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jgh.12377","article-title":"Effect modification of body mass index and body fat percentage on fatty liver disease in a Japanese population","volume":"29","author":"Saida","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0036","doi-asserted-by":"crossref","first-page":"733","DOI":"10.14309\/ajg.0000000000001030","article-title":"Impact of body weight gain on the incidence of nonalcoholic fatty liver disease in nonobese Japanese individuals","volume":"116","author":"Yamada","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jech-2021-216728","article-title":"Joint effect of changes in physical activity and weight on incident non-alcoholic fatty liver disease","author":"Tsai","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0037","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0039","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/liv.13933","article-title":"Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: a population-based cohort study","volume":"39","author":"Zhu","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0041","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2016.178","article-title":"Metabolically healthy obesity and the development of nonalcoholic fatty liver disease","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0042","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1053\/j.gastro.2007.03.039","article-title":"Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma","volume":"132","author":"Kim","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0043","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1194\/jlr.M079533","article-title":"Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein","volume":"59","author":"Wang","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0044","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1128\/JVI.02604-15","article-title":"Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein","volume":"90","author":"Wu","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canlet.2017.02.003","article-title":"Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein","volume":"392","author":"Zhang","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0046","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"Shaheen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0047","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.omtn.2019.12.023","article-title":"A discovery of clinically approved formula FBRP for repositioning to treat HCC by inhibiting PI3K\/AKT\/NF-\u03baB activation","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0048","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcmgh.2020.04.009","article-title":"Inhibition of hepatic bile acid uptake by myrcludex B promotes glucagon-like peptide-1 release and reduces obesity","volume":"10","author":"Donkers","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0049","article-title":"Tenofovir alafenamide attenuates effects of diabetes and body mass on serum alanine aminotransferase activities in patients with chronic hepatitis B","author":"Sripongpun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.13804","article-title":"Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B","volume":"44","author":"Seto","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0052","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3350\/cmh.2018.0054","article-title":"Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.hbpd.2021.06.009_bib0051","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13271","article-title":"The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response","volume":"37","author":"Charatcharoenwitthaya","year":"2017","journal-title":"Liver Int"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387221001223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387221001223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:42:12Z","timestamp":1761493332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387221001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1499387221001223"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2021.06.009","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2021.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}